Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-10. (Canceled)

11. (Currently Amended) A method of ~~preventing or~~ treating a disorder characterized by amyloid deposition of Aβ peptide in a mammalian subject, comprising administering to the subject a dosage of an agent effective to produce an immune response comprising antibodies against an amyloid component characteristic of said disorder, wherein the amyloid component is Aβ peptide and an adjuvant that augments the immune response to the Aβ peptide, and thereby ~~preventing or~~ treating the disorder .

12-13: (Canceled)

14. (Previously Presented) The method of claim 11, wherein said agent induces an immune response directed against a neoepitope formed by said amyloid component with respect to amyloid precursor protein.

15. (Canceled)

16. (Previously Presented) The method of claim 58, wherein said agent is Aβ or a fragment thereof.

17. (Canceled)

18. (Currently Amended) The method of claim 16, wherein said administering includes administering a second amyloid component[[s]].

19. (Previously Presented) The method of claim 58, wherein said agent is a peptide linked to a carrier protein.

20. (Canceled)

21. (Previously Presented) The method of claim 11, wherein said adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, and alum.

22. (Previously Presented) The method of claim 11, wherein said immune response is characterized by a serum titer of the antibodies of at least 1:1000 with respect to said amyloid component.

23. (Previously Presented) The method of claim 22, wherein said serum titer of the antibodies is at least 1:5000 with respect to said amyloid component.

24. (Previously Presented) The method of claim 11, wherein said immune response is characterized by a serum titer of the antibodies corresponding to greater than about four times higher than a serum titer of anti-Aβ antibodies measured in a pre-treatment control serum sample.

25. (Previously Presented) The method of claim 24, wherein said serum titer of the antibodies is measured at a serum dilution of about 1:100.

26-57: (Canceled)

58. (Currently Amended) The method of claim 11, wherein the disorder is hereditary Alzheimer's disease, Down's syndrome, hereditary cerebral hemorrhage amyloidosis (Dutch type), sporadic cerebral amyloid angiopathy, or inclusion body myositis.

59. (New) A method of prophylaxis of a disorder characterized by amyloid deposition of Aβ peptide in a mammalian subject, comprising administering to the subject a dosage of an agent effective to produce an immune response comprising antibodies against an amyloid component characteristic of said disorder, wherein the amyloid component is Aβ peptide and an adjuvant that augments the immune response to the Aβ peptide, and thereby effecting prophylaxis of the disorder.

60. (New) The method of claim 59, wherein said agent induces an immune response directed against a neoepitope formed by said amyloid component with respect to amyloid precursor protein.

61. (New) The method of claim 59, wherein said agent is Aβ or a fragment thereof.

62. (New) The method of claim 61, wherein said administering includes administering a second amyloid component.

63. (New) The method of claim 59, wherein said agent is a peptide linked to a carrier protein.

64. (New) The method of claim 59, wherein said adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, and alum.

65. (New) The method of claim 59, wherein said immune response is characterized by a serum titer of the antibodies of at least 1:1000 with respect to said amyloid component.

66. (New) The method of claim 59, wherein said serum titer of the antibodies is at least 1:5000 with respect to said amyloid component.

67. (New) The method of claim 59, wherein said immune response is characterized by a serum titer of the antibodies corresponding to greater than about four times higher than a serum titer of anti-Aβ antibodies measured in a pre-treatment control serum sample.

68. (New) The method of claim 59, wherein said serum titer of the antibodies is measured at a serum dilution of about 1:100.

69. (New) The method of claim 59, wherein the disorder is hereditary Alzheimer's disease, Down's syndrome, hereditary cerebral hemorrhage(Dutch type), sporadic cerebral amyloid angiopathy, or inclusion body myositis.

70. (New) The method of claim 11, wherein the patient has a known genetic risk of the disorder.

71. (New) The method of claim 59, wherein the patient has a known genetic risk of the disorder.